One company that has been gaining acclaim in their industry, but not on Wall Street, is NanoViricides. An odd series of events is causing confusion in the marketplace.

NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. Based in Connecticut, the young company has gained raved reviews for its HIVCode which could result in a functional cure for HIV/AIDS. Besides the HIVCode, NanoViricides has been making progress in all aspects of their company.

NanoViricides has reported that it is well-financed into the future and its game changing anti-viral and drug programs have continued to develop successfully. Recently, Nano announced that is raised $4.3 million in equity financing which should be sufficient for 18 months or beyond December 2010.

Leading the way at Nano is Dr. Eugene Seymour who serves as their CEO. Dr. Seymour is a renowned name in the industry

Anil Diwan, Ph.D., president of NanoViricides, Inc., a development stage company creating special purpose nanomaterials for viral therapy, revealed the remarkable potential of this new class of drugs for the treatment of viral disease in a presentation given at the 8th annual NanoBusiness Conference in Chicago recently.

NanoViricides has created a class of drug candidates, under the Nanoviricide™ name, that comes as close as anything to the sought after “magic bullet”, able to zero in on specific virus particles and dismantle them. The company is already developing drugs against a number of viral diseases, including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital herpes, and viral diseases of the eye. They are also working on drugs against Hepatitis C, Rabies, and the deadly Ebola virus, among others.

Dr. Diwan described the remarkable way the new drugs are able to focus in and destroy virus particles. “Viruses